Meirson T, Goldstein DA, Gyawali B, Tannock IF. Review of the monarchE trial suggestsno evidence to support use of adjuvant abemaciclib in women with breast cancer.
Lancet Oncol. 2023 May 2:S1470-2045(23)00165-1. doi:
10.1016/S1470-2045(23)00165-1. Epub ahead of print. PMID: 37146621. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00165-1/fulltext
JohnstonSRD, Tolaney SM, O'Shaughnessy J, Rastogi P, Harbeck N, Martin M. Review of the
monarchE trial suggests no evidence to support use of adjuvant abemaciclib in
women with breast cancer - Authors' reply. Lancet Oncol. 2023 May
2:S1470-2045(23)00214-0. doi: 10.1016/S1470-2045(23)00214-0. Epub ahead of
print. PMID: 37146620. https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(23)00214-0.pdf
LashenAG, Toss MS, Mongan NP, Green AR, Rakha EA. The clinical value of progesterone
receptor expression in luminal breast cancer: A study of a large cohort with
long-term follow-up. Cancer. 2023 Apr 15;129(8):1183-1194. doi:
10.1002/cncr.34655. Epub 2023 Jan 18. PMID: 36653923. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34655